Form 8-K - Current report:
SEC Accession No. 0001494650-24-000177
Filing Date
2024-12-30
Accepted
2024-12-30 16:32:14
Documents
15
Period of Report
2024-12-30
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K optn-20241230.htm   iXBRL 8-K 32885
2 EX-3.1 ex31certificateofamendment.htm EX-3.1 17150
6 optn-20241230_g1.jpg GRAPHIC 10067
  Complete submission text file 0001494650-24-000177.txt   208484

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT optn-20241230.xsd EX-101.SCH 1785
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT optn-20241230_lab.xml EX-101.LAB 22592
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT optn-20241230_pre.xml EX-101.PRE 13060
17 EXTRACTED XBRL INSTANCE DOCUMENT optn-20241230_htm.xml XML 2822
Mailing Address 777 TOWNSHIP LINE ROAD SUITE 300 YARDLEY PA 19067
Business Address 777 TOWNSHIP LINE ROAD SUITE 300 YARDLEY PA 19067 267-364-3500
OptiNose, Inc. (Filer) CIK: 0001494650 (see all company filings)

EIN.: 421771610 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38241 | Film No.: 241590232
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)